Granisetron 1 mg Tablets Under Fasting Conditions

NCT ID: NCT00834717

Last Updated: 2024-08-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-09-30
• Study Completion Date: 2005-09-30

Brief Summary

The objective of this study is to evaluate the comparative bioavailability between granisetron hydrochloride 1 mg tablets (Teva Pharmaceuticals USA) and Kytril® 1 mg tablets (Roche, USA), after a single-dose in health subjects under fasting conditions.

Detailed Description

Criteria for Evaluation: FDA Bioequivalence Criteria

Statistical Methods: FDA bioequivalence statistical methods

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Granisetron

Granisetron 1 mg Tablet (test) dosed in first period followed by Kytril® 1 mg Tablet (reference) dosed in second period

Group Type: EXPERIMENTAL

Granisetron hydrochloride 1 mg tablets

Intervention Type: DRUG

2 x 1 mg, single dose fasting

Kytril®

Kytril 1 mg Tablet (reference) dosed in first period followed by Granisetron 1 mg Tablet (test) dosed in second period

Group Type: ACTIVE_COMPARATOR

Kytril® 1 mg tablets

Intervention Type: DRUG

2 x 1 mg, single dose fasting

Interventions

Granisetron hydrochloride 1 mg tablets

2 x 1 mg, single dose fasting

Intervention Type: DRUG

Kytril® 1 mg tablets

2 x 1 mg, single dose fasting

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy, non-smoking, male and female subjects, 18 years of age or older.
• BMI ≥ 19 and ≤ 30.
• No significant diseases or clinically significant findings in a physical examination.
• No clinically significant abnormal laboratory values.
• No clinically significant findings in the 12-lead electrocardiogram (ECG).
• No clinically significant findings from the vital signs measurement.
• Be informed of the nature of the study and given written consent prior to receiving any study procedure.

Negative for:

• HIV.
• Hepatitis B surface antigen and Hepatitis C antibody.
• Urine drugs of abuse test (marijuana, amphetamines, barbiturates, cocaine, opiates, benzodiazepines and methadone).
• Urine cotinine test.
• Serum HCG consistent with pregnancy (females only).

Females who participate in this study are:

• unable to have children (e.g. post-menopausal, tubal ligation, hysterectomy) OR
• willing to remain abstinent [not engage in sexual intercourse] OR
• willing to use an effective method of double-barrier birth control [partner using condom and female using diaphragm, contraceptive sponge, spermicide or IUD]
• Females who participate in this study are not pregnant and/or non-lactating.

Exclusion Criteria

• Known history or presence of any clinically significant medical condition.
• Known or suspected carcinoma.
• On a special diet within 4 weeks prior to drug administration (e.g. liquid, protein, raw food diet).
• Participated in another clinical trial or received an investigational product within 30 days prior to drug administration.
• Donated up to 250 mL of blood within the previous 30 days OR Donated from 251 to 500 mL of blood in the previous 45 days OR Donated more than 500 mL of blood in the previous 56 days (based on the Canadian Blood Services guideline for blood donation).
• Females taking oral or transdermal hormonal contraceptives within 14 days preceding period 1 dosing OR females having taken implanted or injected hormonal contraceptives within 6 months prior to period 1 dosing.
• Requirement of any non-topical medication (prescription and/or over-the-counter) on a routine basis.
• Difficulty fasting or consuming the standard meals.
• Do not tolerate venipuncture.
• Unable to read or sign the ICF.

Known history or presence of:

• Hypersensitivity or idiosyncratic reaction to granisetron hydrochloride and/or any other drug substances with similar activity.
• Alcoholism within the last 12 months.
• Drug dependence and/or substance abuse.
• Use of tobacco or nicotine-containing products, within the last 6 months.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Teva Pharmaceuticals USA

INDUSTRY

Sponsor Role: lead

Principal Investigators

Xueyu (Eric) Chen, M.D., Ph. D.

Role: PRINCIPAL_INVESTIGATOR

Pharma Medica

Locations

Pharma Medica Research Inc.

Toronto, Ontario, Canada

Countries

Canada

Other Identifiers

2005-1028

Identifier Type: -

Identifier Source: org_study_id